The vaccination programme is moving forward and we know many people affected by lymphoma will have the opportunity to have the COVID-19 vaccine shortly, if they haven’t already had it. All people affected by lymphoma are recommended to have the vaccine.
In this webinar a panel of experts, including three haematologists and a doctor working at the Medicines and Healthcare products Regulatory Agency (MHRA), talk about how the vaccines work, how they have been trialled and the protection they should offer, specifically focussing on people affected by blood cancers.
The panel explained that because the vaccine relies on developing an immune response, it can take around 3 weeks for there to be a level of protection. There was discussion over the level of protection offered by the vaccines to people affected by blood cancer and also around infectivity and the chances of passing on the virus if you catch it. This is why the panel recommend that even after you’ve had the vaccine you should continue to be cautious, and closely follow the government guidelines.
19 January 2021